Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.
Extracellular volume fraction
Fibrosis
Human immunodeficiency virus
Inflammation
Left atrial volume
Myocardial disease
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
03 09 2022
03 09 2022
Historique:
received:
05
07
2022
accepted:
26
08
2022
entrez:
3
9
2022
pubmed:
4
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Infection with human immunodeficiency virus (HIV) is associated with higher risk for myocardial disease despite modern combination antiretroviral therapy (cART). Factors contributing to this excess risk, however, remain poorly characterized. We aimed to assess cross-sectional relationships between elevations of left atrial volume index (LAVI) and myocardial extracellular volume (ECV) fraction that have been reported in persons living with HIV and levels of circulating biomarkers of inflammation, fibrosis, and myocyte stretch among persons living with and without HIV (PLWH, PLWOH). Participants from three cohorts of PLWH and PLWOH underwent cardiovascular magnetic resonance imaging for measurement of LAVI and ECV. Levels of circulating proteins (IL-6, sCD14, galectin-3, NT-proBNP, GDF-15, TIMP-2, MMP-2, and hsTnI) were measured using immunoassays. Associations were assessed using logistic and linear regression, adjusting for demographics, substance use, and clinical characteristics. Among 381 participants with and without HIV, median age (IQR) was 55.1 (51.2, 58.4) years, 28% were female, 69% were Black, and 46% were current smokers. Sixty-two percent were PLWH (n = 235), of whom 88% were receiving cART and 72% were virally suppressed. PLWH had higher levels of sCD14 (p = < 0.001), GDF-15 (p = < 0.001), and NT-proBNP (p = 0.03) compared to PLWOH, while levels of other biomarkers did not differ by HIV serostatus, including IL-6 (p = 0.84). Among PLWH, higher sCD14, GDF-15, and NT-proBNP were also associated with lower CD4 + cell count, and higher NT-proBNP was associated with detectable HIV viral load. NT-proBNP was associated with elevated LAVI (OR: 1.79 [95% CI: 1.31, 2.44]; p < 0.001) with no evidence of effect measure modification by HIV serostatus. Other associations between HIV-associated biomarkers and LAVI or ECV were small or imprecise. Our findings suggest that elevated levels of sCD14, GDF-15, and NT-proBNP among PLWH compared to PLWOH observed in the current cART era may only minimally reflect HIV-associated elevations in LAVI and ECV. Future studies of excess risk of myocardial disease among contemporary cohorts of PLWH should investigate mechanisms other than those connoted by the studied biomarkers.
Sections du résumé
BACKGROUND
Infection with human immunodeficiency virus (HIV) is associated with higher risk for myocardial disease despite modern combination antiretroviral therapy (cART). Factors contributing to this excess risk, however, remain poorly characterized. We aimed to assess cross-sectional relationships between elevations of left atrial volume index (LAVI) and myocardial extracellular volume (ECV) fraction that have been reported in persons living with HIV and levels of circulating biomarkers of inflammation, fibrosis, and myocyte stretch among persons living with and without HIV (PLWH, PLWOH).
METHODS
Participants from three cohorts of PLWH and PLWOH underwent cardiovascular magnetic resonance imaging for measurement of LAVI and ECV. Levels of circulating proteins (IL-6, sCD14, galectin-3, NT-proBNP, GDF-15, TIMP-2, MMP-2, and hsTnI) were measured using immunoassays. Associations were assessed using logistic and linear regression, adjusting for demographics, substance use, and clinical characteristics.
RESULTS
Among 381 participants with and without HIV, median age (IQR) was 55.1 (51.2, 58.4) years, 28% were female, 69% were Black, and 46% were current smokers. Sixty-two percent were PLWH (n = 235), of whom 88% were receiving cART and 72% were virally suppressed. PLWH had higher levels of sCD14 (p = < 0.001), GDF-15 (p = < 0.001), and NT-proBNP (p = 0.03) compared to PLWOH, while levels of other biomarkers did not differ by HIV serostatus, including IL-6 (p = 0.84). Among PLWH, higher sCD14, GDF-15, and NT-proBNP were also associated with lower CD4 + cell count, and higher NT-proBNP was associated with detectable HIV viral load. NT-proBNP was associated with elevated LAVI (OR: 1.79 [95% CI: 1.31, 2.44]; p < 0.001) with no evidence of effect measure modification by HIV serostatus. Other associations between HIV-associated biomarkers and LAVI or ECV were small or imprecise.
CONCLUSIONS
Our findings suggest that elevated levels of sCD14, GDF-15, and NT-proBNP among PLWH compared to PLWOH observed in the current cART era may only minimally reflect HIV-associated elevations in LAVI and ECV. Future studies of excess risk of myocardial disease among contemporary cohorts of PLWH should investigate mechanisms other than those connoted by the studied biomarkers.
Identifiants
pubmed: 36057773
doi: 10.1186/s12872-022-02835-y
pii: 10.1186/s12872-022-02835-y
pmc: PMC9441072
doi:
Substances chimiques
Biomarkers
0
Growth Differentiation Factor 15
0
Interleukin-6
0
Lipopolysaccharide Receptors
0
Peptide Fragments
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
393Subventions
Organisme : NHLBI NIH HHS
ID : U01 HL146205
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126552
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007227
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA036297
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146201
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146193
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI120834
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146240
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Front Immunol. 2020 May 19;11:951
pubmed: 32508832
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
J Infect Dis. 2011 Oct 15;204(8):1227-36
pubmed: 21917896
Open Forum Infect Dis. 2017 Nov 28;4(4):ofx262
pubmed: 29308409
Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e30-e37
pubmed: 30673349
Radiology. 2016 Mar;278(3):714-22
pubmed: 26485617
J Infect Dis. 2020 Mar 28;221(8):1315-1320
pubmed: 31100122
Prog Cardiovasc Dis. 2020 Mar - Apr;63(2):134-141
pubmed: 31987806
Nat Rev Cardiol. 2020 Nov;17(11):698-717
pubmed: 32444692
J Am Heart Assoc. 2014 May 28;3(3):e000844
pubmed: 24870935
J Infect Dis. 2013 Apr 15;207(8):1221-5
pubmed: 23322858
JAMA Cardiol. 2017 May 1;2(5):536-546
pubmed: 28384660
JACC Heart Fail. 2019 Feb;7(2):98-108
pubmed: 30704613
J Am Coll Cardiol. 2017 Dec 26;70(25):3102-3109
pubmed: 29268924
J Am Heart Assoc. 2013 Nov 07;2(6):e000399
pubmed: 24200688
J Cardiovasc Magn Reson. 2020 Dec 14;22(1):87
pubmed: 33308262
J Infect Dis. 2014 Oct 15;210(8):1248-59
pubmed: 24795473
J Am Coll Cardiol. 2021 Feb 9;77(5):572-574
pubmed: 33538255
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
J Am Heart Assoc. 2021 Apr 6;10(7):e019709
pubmed: 33749311
J Am Heart Assoc. 2016 Jun 27;5(6):
pubmed: 27353609
J Cardiovasc Magn Reson. 2013 Oct 14;15:92
pubmed: 24124732
Circulation. 2010 Oct 5;122(14):1387-95
pubmed: 20855664
Circulation. 2019 Jul 9;140(2):e98-e124
pubmed: 31154814
Hypertension. 2018 Oct;72(4):902-908
pubmed: 30354713
J Infect Dis. 2015 Nov 15;212(10):1544-51
pubmed: 25964507
J Am Heart Assoc. 2021 Sep 21;10(18):e021268
pubmed: 34493058
PLoS One. 2016 May 12;11(5):e0155100
pubmed: 27171281
Am J Cardiol. 2016 Jan 15;117(2):214-20
pubmed: 26639041
J Am Heart Assoc. 2019 Jul 16;8(14):e012241
pubmed: 31266386
Open Forum Infect Dis. 2020 Dec 07;8(1):ofaa600
pubmed: 33511232
Cytokine Growth Factor Rev. 2019 Aug;48:24-31
pubmed: 31296363
Eur Heart J Cardiovasc Imaging. 2021 Jul 20;22(8):888-895
pubmed: 33693554
Circulation. 2018 Sep 11;138(11):1100-1112
pubmed: 29967196
Circulation. 2012 Sep 25;126(13):1596-604
pubmed: 22907935
J Am Heart Assoc. 2021 Jun;10(11):e018767
pubmed: 33998251
Am J Hypertens. 2021 Jun 22;34(6):626-635
pubmed: 33491080
Circ Cardiovasc Imaging. 2016 Mar;9(3):e004091
pubmed: 26951603
J Am Coll Cardiol. 2007 Sep 11;50(11):1054-60
pubmed: 17825714
J Infect Dis. 2014 Oct 15;210(8):1228-38
pubmed: 24755434
J Cardiovasc Electrophysiol. 2017 Jul;28(7):796-805
pubmed: 28429529
JACC Heart Fail. 2015 Aug;3(8):591-9
pubmed: 26164679
JACC Heart Fail. 2019 Feb;7(2):109-111
pubmed: 30704602
AIDS. 2015 Feb 20;29(4):463-71
pubmed: 25630041
Circ Heart Fail. 2010 Jan;3(1):132-9
pubmed: 19933410
J Am Coll Cardiol. 2013 Oct 1;62(14):1280-1287
pubmed: 23871886
J Infect Dis. 2017 May 1;215(9):1352-1361
pubmed: 28199691
Arch Intern Med. 2011 Apr 25;171(8):737-43
pubmed: 21518940
Front Physiol. 2020 Sep 15;11:529075
pubmed: 33041853
Curr Heart Fail Rep. 2017 Aug;14(4):235-250
pubmed: 28707261
Circ Cardiovasc Imaging. 2016 Mar;9(3):e004430
pubmed: 26951605
Heart. 2012 Jul;98(13):1007-13
pubmed: 22447464
J Am Heart Assoc. 2012 Apr;1(2):
pubmed: 23130122
Yonsei Med J. 2010 Mar;51(2):151-63
pubmed: 20191004
N Engl J Med. 2021 Jun 17;384(24):2306-2316
pubmed: 34133860
Sci Rep. 2019 Dec 27;9(1):20168
pubmed: 31882822